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of PBPC. Several European studies had demonstrated a correla- 
tion between precol lect ion CD34+ cells and the nmnber  of 
CD34+ cells collected. However, it is not standard of practice to 
measure preCD34+ counts and base decisions regarding leuka- 
pheresis procedures on these values. In order to investigate the 
most cost effective method and to minimize number of leuka- 
pheresis procedures for optimal PBPC collection, we retrospec- 
tively analyzed data from 42 patients with hematologic malignan- 
cies. Patient diagnoses included nmltiple myeloma, lymphoma nd 
leukemia. Chemotherapy  mobi l izat ion regimens included 
cyclophosphamide, ICE (ifosfamide, carboplatinum and etopo- 
side) and high dose cytarabine and etoposide. G-CSF was given at 
10mcg/kg/day. Several patients were mobilized with growth factor 
alone. Large volume apheresis procedures were done. Three main 
parameters were monitored prior to each apheresis procedure, the 
YVBC, the preCD34+ count and the CD34+ cells collected. There 
was a significant correlation between the preCD34+ count and the 
apheresis CD34+ cell yield. The study indicated that a collection 
of 2.5 X 10 E 6/kg CD34+ cells was obtained in majority of the 
patients if the preCD34+ count was >20/ul. We were unable to 
collect 2.5 X 10 E 6/kg if preCD34 counts were < 5/ul despite 
numerous leukapheresis procedures. If preCD34 counts were 
more than 75-85/ul patients were able to collect 5 X 10 E 6 
CD34+/kg cells in one large volmne procedure. We also noticed a 
weak correlation between the WBC and the preCD34+ count. A 
WBC of 5k/uI or more was noted in most patients who had 
preCD34+ cells of > 10/ul. From our study, we proposed the most 
cost effective method to find the optimal timing for starting PBPC 
collections is to monitor initially with WBC until the count is 
5k/ul. Subsequently, preCD34+ cell count should be used for con- 
tinued monitoring. Leukapheresis i initiated when preCD34+ 
count are > 20/ul in order to collect sufficient CD34+ cells. 
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AUTOLOGOUS BLOOD AND MARROW TRANSPLANTATION (BMT) IN 
OLDER ADULTS (60 YEARS AND OLDER) 
Bm'imz, C. 1; Milh'r, I4/.Ed; 3/lcMillmz, R.2; A~drey, j.s; MeiseTzberg, 
B/; A/lasol~, J.Rd 1. Hematology m~d Medical Omology, Scripps Clinic, 
La ffolla, CA, 2. The Scripps Research Institme, La Jolla, CA; 
3. GreeJzbamn Career Center, BMtimove, ~/ID. 
From April 1994 to July 2002 we performed autologous BMT 
on 82 patients 60 years of age and older for a variety of condi- 
tions. Thirty-six males and 46 females with a median age of 63 
(range 60 to 74) were given a total of 100 transplants. Indica- 
tions for transplant included lymphoma (26), multiple myeloma 
(22), breast cancer (20), acute myelogenous leukemia (7), amy 
loidosis (5), and Hodgkin's disease (2). A variety of preparative 
regimens were employed as shown below. One patient received 
marrow plus peripheral  blood stem cells (PBSC), while 81 
received PBSC only. Priming for mobilization of PBSC includ- 
ed CY plus G CSF and GM-CSF (51), G-CSF alone (20), CY 
plus G-CSF  (I2), VP16 plus G-CSF  (2), and rebound from 
CHOP (i). The median nmnber of days to collect the target 
PBSC was 2 (range 1 to 7). Four patients had to be remobilized 
due to insufficient collection on the first attempt, while 37 
patients required only one day of collection to reach the target. 
A median of 5.21 x i0C'/kg CD34 positive cells (range 1.42 to 
40.57) and 3.80 x 106/kg CD34 positive cells (range 1.40 to 
40.57) were collected and infused, respectively. All patients had 
leukocyte recovery with a median time to ANC > 500 of 10 days 
(range 8 to 16). Recovery of platelets > 50 occurred in 93 trans- 
plants at a median of 18 days (range 12 to 259); in seven trans- 
plants (six pts; three AML, three lymphoma) platelet recovery to 
> 50 did not occur. Fifty-one of 77 evaluable patients (66%) 
achieved a complete response after transplant. Overall survival 
and disease free survival at three years is 44.6% (95% CI 31.6- 
57.6) and 24.2% (95% C1 13.9-34.5), respectively. Forty-five 
patients are alive and only two deaths were attributed to toxici- 
ties related to autologous transplant (VOD - one pt, ARDS - 
one pt). Our experience with transplantation i this group of 
patients has been favorable and no upper age limit has been 
identified. 
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NOVEL HIGH DOSE CHEMOTHERAPY REGIMEN FOR AUTOLOGOUS 
TRANSPLANT IN PATIENTS WITH HODGKIN'S DISEASE 
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B.2; Jztckett, 3d. z; Lo,go, ~.J I. University of Fffisco~sin, MaclisoTz, T'VI; 
2. ~/licldletoJz Memorial Vetemlls Hospita L Madison, HI7; 3. Mic,{,igal~ 
Community Blood Cemers, Grand Rapids, [VII. 
High dose chemotherapy (HDCT)  followed by autologous 
hematopoietic stem cell (HSC) rescue is an accepted treatment for 
relapsed or refractory Hodgkin's Disease (HD). Many patients 
with HD have had prior radiation therapy which precludes the use 
of total body" irradiation (TBI) in the preparative regimen. Multi- 
ple HDCT regimens without TBI have been used, most common- 
ly CBV and BEAM, with reported overall survival (OS) and dis- 
ease free survival (DFS) rates ranging from 30 to 68% and 25 to 
50%, respectively, depending on length of follow-up and disease 
status (chemosensitive or chemorefractory) at transplant. The 
most commonly reported regimen-related to,c i ty (RRT) is inter- 
stitial pneumonitis related to carmustine. At the University of 
Wisconsin Hospital and Clinics (U~VHC) a novel HDCT regi- 
men of thiotepa nd etoposide was developed for use in HD and 
Non-Hodgkin's Lymphoma and consists of thiotepa 300rag/m2 
and etoposide 700rag/m2 given consecutively on days -6, -5, and - 
4. Since 1987, f i fty-three patients with HD have undergone 
HDCT and autologous HSC rescue utilizing this reginren. Medi- 
an age was 33 years, and the majority of patients (89%) had nodu- 
lar sclerosing HD. At the time of transplant 9 (I7%) patients were 
in complete remission, 30 (57%) patients were in partial remis- 
sion, and 11 (21%) patients were refractory to salvage therapy. 
Eight ( i5%) were considered primary induction failures, and 6 
(11%) were in second or third relapse. Three patients were in 
untreated relapse. Response to induction therapy was < I2 months 
in 32 (60%) patients. With a median follow-up of 45.7 months, 
five year OS is 59% (95%CI, 35-82%), and DFS is 36% (95%CI, 
4-67%). The most common RRT was reversible gastrointestinal 
toxicity. Grade III stomatitis occurred in 60%. There was no 
grade IV stomatitis. Other grade III toxicities included febrile 
neutropenia (98%), thrombosis (7%), and electrolyte abnormali- 
ties (16.7%). One patient died before day +100 due to progressive 
HD, but there were no deaths due to RRT. Two patients have 
developed secondary myelodysplasia. No cases of interstitial pneu- 
monitis occurred, and no patients developed VOD. In conclusion, 
thiotepa and etoposide is a novel HDCT regimen for use in 
patients with relapsed or refractory HD which offers low RRT 
and equivalent long-term OS and DFS compared to other report- 
ed HDCT regimens. 
154 
THE IMPACT OF STEM CELL TRANSPLANTATION ON MANTLE CELL 
LYMPHOMA 
LogsdoTz, 3l.Sd; Greet, ff.p.1; Goodma,, S.A.t; Vztsivikala, M. 1; 
HamiltoJ~, K.2; SchueJlillg, F.Gd; ffagasia, M.H.S; Movgmz, D.Sd; 
IGTssim, A.s; Stein, R.SJ; l~IcCurley, T.L. 2 1. T'~nderbilt - [Iematol- 
ogy/Oncology, Nashville, TN, 2. Vamlert, ih Pathology, Nashville, TN. 
Background: Variable r sults with autologous and allogeneic 
stem cell transplantation for mantle ceil lymphoma have been 
reported by single institutions. Methods: We analyzed ata on 23 
patients who underwent a total of 24 peripheral blood stem cell 
and bone marrow transplants at Vanderbilt University Hospital 
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and the Nashville Veterans Affairs Hospital from 1994 to 2002. 
Central pathologic review was performed on biopsies from 12 
patients. All but two patients presented with advanced stage at 
diagnosis. Median age at transplant for the autologous and allo- 
geneic groups was 53.5 and 49.5 years, respectively. A total of 17 
autologous, 1 syngeneic, and 6 alIogeneic transplants were per- 
formed. Five patients underwent autologous transplantation in 
first complete remission. Results: In the autologous group, median 
overall survival was 4.75 years (95% C.I. 3.7 to 5.8y) and median 
survival from transplant was 2.5 years (95% C.I. 1.3 to 3.7y). The 
Kaplan-Meier estimate of 5-year overall survival was 41% (95% 
C.I. 10% to 72%). in the allogeneic group, 4 patients have died. 
Post-transplant survival ranged from 13 days to 3.4 years. 
Chemosensitivity, defined as the maintenance of at least a partial 
response after the last chemotherapy regimen until the date of 
autologous transplant, was associated with improved overall sur- 
vival by log-rank analysis (p=.0005). For these 13 patients the esti- 
mated 5-year overall survival was 56% (95% C.I. 17% to 95%). 
Post-transplant survival was also significantly prolonged in this 
group (median 3.5 years vs. 319 days, p<.0001, 95% C.I. 1.6 to 
5.4y vs. 26d to 1.Ty). Conclusions: The longest overall survival 
occurred in patients with chemosensitive disease who received 
autologous transplantation. Neither the use of total-body irradia- 
tion, fewer than four pre transplant chemotherapy regimens, nor 
transplant in first remission was found to predict for improved 
survival. Although the confidence intervals are wide, these results 
support he hypothesis that patients with chemosensitive mantle 
cell lymphoma may realize a significant survival benefit from 
autologous transplantation. 
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EX VIVO ACTIVATION AND EXPANSION OF T CELLS FROM THE 
PERIPHERAL BLOOD OF MULTIPLE MYELOMA PATIENTS USING THE 
XCELLERATE TM PROCESS 
F~'oblich, M. W. 1¢ 17escio, R. 2; Be're~Tsolz, J. 2; Ra~w~z~'se~, A. ;t~da~msz, 
D3; Roehrs, H.t; ~VIa'rkha~, E J; Gree~z, CJ; Be~'e~zso~z, R.ff 3; Bo~yha- 
di, 3/i. ~ 1. X~te Ther, tpies, Seattle, fu, q; 2. Cedars-Signal Medical Ce~- 
te~', Los A*zgeles, CA. 
Previous studies in multiple lnyeloma have demonstrated a 
significant association between survival and baseline l vels of 
T cells prior to chemotherapy (Kay et al., Blood 200l) as well 
as lymphocyte counts 15 days following autologous transplan- 
tation (Porrata et al., Blood 2001). Therefore, infusion of large 
numbers of T cells post transplant may improve clinical 
results. We have developed the Xcellerate TM process for the ex 
vivo activation and expansion of T cells using immobilized 
anti-CD3 and anti-CD28 antibodies covalently linked to mag- 
netic beads (Dynabeads® M-450 CD3/CD28 T). Twenty-two 
expansions have been conducted to date using samples from 
multiple myeloma patients who have received avariety of prior 
therapies. The number of T cells increased a mean of 404 fold 
foIlowing an 8-14 day culture process. Purity and viability of T 
ceils post-Xcellerate averaged 97% and 96%, respectively. The 
CD4/CD8 ratio increased from 1.3to 2.1 during the course of 
culture. Significant upregulation of key surface/effector mole- 
cules, including CD25 (IL-2 receptor) and CD154 (CD40 fig- 
and) occurred. Moreover, we have developed a flow cytome- 
try-based assay system for evaluating residual plasma cells in 
the final T cell product. Using analysis of surface marker 
expression, including CD38, CD138, CD45 and CD56, we 
have been unable to detect any plasma cells in the final prod- 
uct within the limits of detection of'the assay (~0.01%). Based 
upon these data, we have initiated a clinical trial to evaluate 
the activity of Xcellerated T Cells in patients with multiple 
myeloma, who are undergoing an autologous stem cell trans- 
plantation. Following induction chemotherapy, patients will 
undergo a leukapheresis to collect T cells for the Xcellerate 
Process. Patients will then undergo stem cell mobilization and 
collection, follwed by high dose chemotherapy with Melpha- 
lan. Patients will then receive a stem cell infusion, followed 
three days later by an infusion of 5-10 x 10 l° autologous 
Xcellerated T Cells. 
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A CLINICAL TRIAL OF GENE TRANSFER TO BONE MARROW CD34+ 
CELLS FROM ADA-DEFICIENT SCID SUBJECTS 
Koh~, D.B.2; Podsateoff G. z, ETzgel, B.C.:; Cavbomrro, D. e, 
&71og'ovzewska, M. 2; C'hoi, C. e; ~/lltzt[, L.1; Sc/]zt'vTzlmz, S. t; Dul~bar, 
C.I; Weir*berg, K.I.:; CmTdotti, F. 1 1. ChildT"eTzs Hospital Los 
A1zgeles/I'~2,ck USC School of ~ledichze, Los A1zgeles, CA; 2. Natiolzal 
Hzt1~lalz GeJ~om, e Resem'eh IiTstimte/NIH, Bethesda, MD. 
Gene transfer to hematopoietic stem ceils (HSC) may provide 
new treatments for genetic diseases of blood cells that are more 
effective or safer than current approaches using allogeneic trans- 
plantation. Retroviral vectors have been used most often to obtain 
stable gene transfer to HSC and there has been incremental 
progress in the design and production of retroviral vectors and in
the methods used to transduce human HSC. Nevertheless, the 
percentages of reconstituting stem cells that can be transduced in
the clinical setting have been too low to be of benefit in most dis- 
orders (e.g.0.01-1%). However, immune deficiencies, including 
severe combined immune deficiency (SCID) and AIDS, may be 
benefited by gene transfer levels in that range, because the gene- 
modified T lymphocytes may have a selective production or sur- 
vival advantage, compared to the non-corrected cells. The high 
rate of immune reconstitution (90%) in subjects with XSCID 
treated with gene transfer firmly demonstrates the benefits of this 
approach. However, the development of a monoclonal T lympho- 
proliferation in one subject underscores the potential toxicities of 
this approach. We are performing a clinical trial for subjects with 
ADA deficient SCID. Four subjects (ages 4-20 years) have been 
enrolled and have undergone the procedure of bone marrow har- 
vest, CD34+ cell isolation, retroviral-mediated ADA gene trans- 
duction, and cell re-infizsion, without serious adverse vent. The 
subjects did not receive marrow cytoreductive conditioning before 
the cell re-infusion and have all continued to receive PEG-ADA 
enzyme replacement therapy. Follow-up times (thur 10/15/02) are 
currently 13, 12, 9 and 8 months. The transferred ADA gene has 
been detected in peripheral blood samples of all subjects, at fre- 
quencies of between 0.001-3%. A staged withdrawal of enzyme 
replacement may begin after the first year. Clinical trials need to 
be performed to determine the relative benefits and risks of gene 
transfer to HSC as a treatment for SCID, compared to approaches 
using allogeneic HSCT. 
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THROMBOTIC MICROANGIOPATHY (TMA), ENCEPHALITIS, AND 
SEIZURES DUE TO HUMAN HERPES VIRUS-6 (HHV-6) REACTIVATION 
IN AN ADULT RECEIVING HIGH-DOSE MELPHALAN WITH AUTOLO- 
GOUS PERIPHERAL STEM CELL TRANSPLANTATION (ASCT) 
Bel~bvd, A.3/I.S; Myles, O.S; Myt.,a~zd, R.C3; ~aJzg,, j.3; Magi~l, A.:, 
~'~'?lsele*zko, J.K. 1 1. ~{~dter Reed AJvzly Medical Ce~zte,-, ~P~lshi*gto*~, 
DC; 2. FValte~" Reed ,*ttwt~ bzstimte of Research, Silver Sprhlg, 3/ID; 
3. Uzzifo*vzled SeJvices U~zfversity, Bethesda, 3lID. 
Herein, we report an adult with TMA associated with HHV-6 
reactivation occurring after ASCT. To our knowledge, this repre- 
sents the first such case in an adult. A 58-year-old female with 
Stage IIIA IgGK multiple myeloma received VAD for 4 cycles fol- 
lowed by" melphalan (200 mg/m2) with ASCT. She was discharged 
on D+16 with resolution of her transplant related toxicities. On 
D+22 she was readmitted with dyspnea, rash, and fever (105 F). 
Despite antibacterial nd antifungal therapy, worsening dyspnea 
and hypotension prompted ICU transfer. Five days later she 
developed TMA and therapeutic plasma exchange (TPE) was ini- 
tiated. Oaa D+28 mental status (MS) changes developed. Head CT 
and EEG were negative. Lumbar puncture (LP) revealed a CSF 
protein of 74. On D+32, a generalized seizure occurred. TPE was 
co~atinued without improvement in thrombocytopenia or her MS 
despite normalization of her LDH, haptoglobin and total biliru 
bin. She required intubation for a depressed MS and another 
seizure. An EEG was consistent with an encephalopathy, and a 
brain MRI showed a right temporal lobe infarct. Serum PCR was 
negative for CMV but positive for HHV-6. Repeat LP demon- 
strated aprotein of 597, a negative CMV antibody, and CSF PCR 
for HSV1, HSV2 were negative but strongly positive for HHV-6 
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